Key result
Recombinant human soluble thrombomodulin combined with high-dose methylprednisolone did not reduce in-hospital mortality compared to methylprednisolone alone in patients with acute exacerbation of idiopathic pulmonary fibrosis.
Why the study?
Acute exacerbation of idiopathic pulmonary fibrosis is the leading cause of death among patients with IPF, but there is no established treatment for this condition.
Does recombinant human soluble thrombomodulin added to high-dose methylprednisolone reduce in-hospital mortality in adult patients with acute exacerbation of idiopathic pulmonary fibrosis requiring mechanical ventilation?
Observational (n=2,814)
Yes
Does recombinant human soluble thrombomodulin added to high-dose methylprednisolone reduce in-hospital mortality in adult patients with acute exacerbation of idiopathic pulmonary fibrosis requiring mechanical ventilation?
In patients with acute exacerbation of idiopathic pulmonary fibrosis requiring mechanical ventilation, the addition of recombinant human soluble thrombomodulin to high-dose methylprednisolone did not improve in-hospital mortality.
Answers are grounded in this paper and cite their sources.
Does not support adding thrombomodulin to methylprednisolone in acute IPF exacerbation; leaves open randomized confirmation of benefit.
BACKGROUND: Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is the leading cause of death among patients with IPF. However, there is no established treatment for this condition. Hence, we aimed to investigate the effectiveness and safety of recombinant human soluble thrombomodulin (rTM) for the treatment of AE-IPF. METHODS: Data were retrospectively collected from the Japanese Diagnosis Procedure Combination database from 1 January 2014 to 31 March 2018. We identified adult patients with IPF who received high-dose methylprednisolone (mPSL) therapy and mechanical ventilation upon admission. Eligible patients (n = 2814) were divided into those receiving high-dose mPSL alone (mPSL alone group, n = 2602) and rTM combined with high-dose mPSL (rTM group, n = 212). A stabilised inverse probability of treatment weighting (IPTW) using propensity scores was performed to compare outcomes between the two groups. The primary outcome was in-hospital mortality, and the secondary outcomes were 14- and 28-day mortality, bleeding events and length of hospital stay. RESULTS: The in-hospital mortality rates of the mPSL alone and rTM groups were 75.9% and 76.9%, respectively. The results did not significantly differ between the two groups after performing a stabilised IPTW. The odds ratio of the rTM group compared to the mPSL alone group was 1.15 (95% confidence interval: 0.71-1.84; p = 0.57). Moreover, the secondary outcomes did not differ significantly between the two groups. CONCLUSIONS: In patients with AE-IPF who developed severe respiratory failure, rTM in addition to high-dose mPSL was not associated with a better outcome.
No takes yet. Share an insight, caveat, or question.
Awano et al. (2022) conducted an observational in Acute exacerbation of idiopathic pulmonary fibrosis (n=2,814). Recombinant human soluble thrombomodulin (rTM) vs. High-dose methylprednisolone alone was evaluated on In-hospital mortality (OR 1.15, 95% CI 0.71-1.84, p=0.57). Recombinant human soluble thrombomodulin combined with high-dose methylprednisolone did not reduce in-hospital mortality compared to methylprednisolone alone in patients with acute exacerbation of idiopathic pulmonary fibrosis.
Synapse has enriched 10 related papers. Consider them for comparative context: